BCMA CAR-T Pipeline Landscape
Focus: Multiple Myeloma Indication
Multiple Myeloma is the second most common hematologic malignancy and is largely considered incurable. The promising results obtained with the bluebird bio’s idecabtagene vicleucel (bb2121) and Janssen - Legend Biotech’s JNJ-68284528 (LCAR-B38M) brought CAR-Ts at the forefront of the clinical research.
B-cell Maturation Antigen (BCMA) is an antigen that has been shown to be specifically expressed in myeloma cells. With the ASH Annual Meeting 2019 close at hand, we performed a comprehensive pipeline analysis of BCMA targeting CAR-Ts in Multiple Myeloma indication.
We had two specific objectives
We identified47 BCMA targeting CAR-Ts
Our detailed analysis of clinical trials from various registries showed that 47 BCMA CAR-Ts are under clinical development by 40 companies. Idecabtagene vicleucel (ide-cel) leads the pack being the ONLY candidate in Phase 3.
The results from the Phase 2 CRB-401 trial, published in May 2019, showed that ide-cil offered an impressive ORR of 85%. However, the median PFS of 11.8 months somewhat disappointed experts who were expecting ide-cel to be a curative therapy.
Could combining BCMA CAR-Ts with another agent increase its efficacy? Notably, only about 30% of trials are investigating BCMA CAR-Ts in combination with another agent. In other words, about 70% of trials are studying BCMA CAR-Ts as monotherapy.
How are these BCMA targeting CAR-Ts differentiated? CAR-T design, target patient pool, or anything else? We will soon publish our findings on this question.
If you are viewing this webpage on mobile, please use Landscape mode for better visual and reading experience.
You can write to us at email@example.com for any clarification.